efimosfermin - Search News

News

GSK, Boston and efimosfermin

GSK to acquire liver disease drug Efimosfermin for up to USD 2 billion

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, have announced that they

Medical Dialogues · 7h

PMLive · 7h

GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

Zacks Investment Research on MSN · 6h

GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug

1don MSN

GSK to buy efimosfermin for up to $2 billion

British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine ...

Pharmabiz14h

GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD

GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD: London, UK Thursday, May 15, 2025, ...

Medscape6d

Once-Monthly Efimosfermin Leads to Significant MASH Improvement in Phase 2 Trial

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results